Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

University of Pennsylvania CAR T cell Responding and Non-responding Patients

ABSTRACT: University of Pennsylvania CAR T cell Responding and Non-responding Patients

PROVIDER: PRJNA494908 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

University of Pennsylvania CAR T cell Responding and Non-responding Patients

Project description:University of Pennsylvania CAR T cell Responding and Non-responding Patients

| PRJNA494907 | ENA

Non-Responding Celiac Disease

Project description:Non-Responding Celiac Disease

| PRJEB65879 | ENA

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

Project description:Purpose: To identify transcriptional changes by RNA-seq in tumor samples, before bevacizumab combination treatment and after bevacizumab combination treatment in both responding and non-responding recurrent glioblastoma patients

2017-04-20 | GSE79671 | GEO

Transcriptomic profiling of NK-92, CAR NK-92, and NR3C1-knockout CAR NK-92 cells following co-culture with CEACAM5⁺ A549 lung cancer cells

Project description:CEACAM5-specific CAR NK-92 cells were engineered to target CEACAM5-expressing lung tumor cells. To study their transcriptional response during tumor engagement, parental NK-92 cells, CEACAM5-CAR NK-92 cells, hydrocortisone-treated CAR NK-92 cells, NR3C1-knockout (cortisol-resistant) CAR NK-92 cells, and hydrocortisone-treated NR3C1-knockout CAR NK-92 cells were co-cultured with CEACAM5⁺ A549 lung cancer cells for 16 hours. Following co-culture, NK-92–derived effector cells were isolated by flow cytometry and processed for bulk RNA sequencing. This dataset captures transcriptional programs associated with CAR activation, hydrocortisone exposure, and glucocorticoid receptor deficiency in NK-92–based effector cells responding to CEACAM5⁺ tumor targets.

2025-12-18 | E-MTAB-16373 | biostudies-arrayexpress

UPenn CAR T cell Responders and Non-responders

Project description:<p>The adoptive transfer of autologous T cells genetically modified to express a CD19-specific, 4-1BB/CD3zeta-signaling chimeric antigen receptor (CAR; CTL019) has shown remarkable activity in patients with B acute lymphoblastic leukemia. Similar therapy can induce long-term remissions for relapsed/refractory chronic lymphocytic leukemia (CLL) patients, but in only a small subset of subjects. The determinants of response and resistance to CTL019 therapy of CLL are not fully understood. We employed next generation sequencing of RNA (RNA-seq) to identify predictive indicators of response to CTL019 treatment. We performed RNA-seq on leukapheresis and manufactured infusion product T cells from patients with heavily pre-treated and high-risk disease. To characterize potency, we also performed RNA-seq on the cellular infusion product after CAR-specific stimulation. Our findings indicate that durable remission in CLL is associated with gene expression signatures of early memory T cell differentiation (e.g., STAT3), while T cells from poorly- or non-responding patients exhibited elevated expression of key regulators of late memory as well as effector T cell differentiation, apoptosis, aerobic glycolysis, hypoxia and exhaustion. These gene expression signatures, along with additional immunological biomarkers, may be used to identify which patients are most likely to respond to cellular therapies and suggest manufacturing modifications that might potentiate the generation of maximally efficacious infusion products.</p>

| phs001707 | dbGaP

Practice Based Opportunities for Weight Reduction Trial at the University of Pennsylvania (POWER_UP_BioLINCC)

Project description:Practice Based Opportunities for Weight Reduction Trial at the University of Pennsylvania (POWER_UP_BioLINCC)

| PRJNA1430855 | ENA

Practice Based Opportunities for Weight Reduction Trial at the University of Pennsylvania (POWER_UP_BioLINCC)

Project description:Practice Based Opportunities for Weight Reduction Trial at the University of Pennsylvania (POWER_UP_BioLINCC)

| PRJNA1430856 | ENA

NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The University of Pennsylvania Cardiovascular Study

Project description:NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The University of Pennsylvania Cardiovascular Study

| PRJNA422006 | ENA

NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The University of Pennsylvania Cardiovascular Study

Project description:NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The University of Pennsylvania Cardiovascular Study